Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 86 entries
Sorted by: Best Match Show Resources per page
Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction.

CJC open

Gupta M, Bell A, Padarath M, Ngui D, Ezekowitz J.
PMID: 33778453
CJC Open. 2020 Nov 16;3(3):361-366. doi: 10.1016/j.cjco.2020.11.008. eCollection 2021 Mar.

BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) carries high morbidity and mortality. Compared with HF with reduced ejection fraction (HFrEF), HFpEF is difficult to diagnose, and lacks evidence-based treatments. In this survey we assessed perceptions of cardiologists,...

Cite
Gupta M, Bell A, Padarath M, et al. Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. CJC Open. 2020;3(3):361-366doi: 10.1016/j.cjco.2020.11.008.
Gupta, M., Bell, A., Padarath, M., Ngui, D., & Ezekowitz, J. (2021). Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. CJC open, 3(3), 361-366. https://doi.org/10.1016/j.cjco.2020.11.008
Gupta, Milan, et al. "Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction." CJC open vol. 3,3 (2021): 361-366. doi: https://doi.org/10.1016/j.cjco.2020.11.008
Gupta M, Bell A, Padarath M, Ngui D, Ezekowitz J. Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. CJC Open. 2020 Nov 16;3(3):361-366. doi: 10.1016/j.cjco.2020.11.008. eCollection 2021 Mar. PMID: 33778453; PMCID: PMC7985003.
Copy Download .nbib Format: NLM
Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials.

Contemporary clinical trials

Harrington J, Gouda P, Ezekowitz J, Mentz RJ.
PMID: 34863929
Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01.

Clinical trials are a cornerstone of modern medicine and form the backbone of evidence that is used to create evidence-based guidelines. Contemporary clinical trials have tended to be quite explanatory, assessing an intervention in ideal conditions with highlyprotocolized interventions,...

Cite
Harrington J, Gouda P, Ezekowitz J, et al. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021;113:106646doi: 10.1016/j.cct.2021.106646.
Harrington, J., Gouda, P., Ezekowitz, J., & Mentz, R. J. (2021). Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemporary clinical trials, 113106646. https://doi.org/10.1016/j.cct.2021.106646
Harrington, Josephine, et al. "Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials." Contemporary clinical trials vol. 113 (2021): 106646. doi: https://doi.org/10.1016/j.cct.2021.106646
Harrington J, Gouda P, Ezekowitz J, Mentz RJ. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01. PMID: 34863929.
Copy Download .nbib Format: NLM
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.

Journal of the American Heart Association

Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O'Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW.
PMID: 34743540
J Am Heart Assoc. 2021 Nov 16;10(22):e021094. doi: 10.1161/JAHA.121.021094. Epub 2021 Nov 06.

Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients with heart failure with reduced ejection fraction, some subgroups may be more...

Cite
Lam CSP, Mulder H, Lopatin Y, et al. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021;10(22):e021094doi: 10.1161/JAHA.121.021094.
Lam, C. S. P., Mulder, H., Lopatin, Y., Vazquez-Tanus, J. B., Siu, D., Ezekowitz, J., Pieske, B., O'Connor, C. M., Roessig, L., Patel, M. J., Anstrom, K. J., Hernandez, A. F., Armstrong, P. W. (2021). Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. Journal of the American Heart Association, 10(22), e021094. https://doi.org/10.1161/JAHA.121.021094
Lam, Carolyn S P, et al. "Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial." Journal of the American Heart Association vol. 10,22 (2021): e021094. doi: https://doi.org/10.1161/JAHA.121.021094
Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O'Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. doi: 10.1161/JAHA.121.021094. Epub 2021 Nov 06. PMID: 34743540; PMCID: PMC8751950.
Copy Download .nbib Format: NLM
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Cardiovascular research

Pol T, Hijazi Z, Lindbäck J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L.
PMID: 34358298
Cardiovasc Res. 2021 Aug 06; doi: 10.1093/cvr/cvab262. Epub 2021 Aug 06.

AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular...

Cite
Pol T, Hijazi Z, Lindbäck J, et al. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2021;doi: 10.1093/cvr/cvab262.
Pol, T., Hijazi, Z., Lindbäck, J., Oldgren, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Lopes, R. D., Yusuf, S., Siegbahn, A., & Wallentin, L. (2021). Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovascular research, . https://doi.org/10.1093/cvr/cvab262
Pol, Tymon, et al. "Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation." Cardiovascular research vol. (2021). doi: https://doi.org/10.1093/cvr/cvab262
Pol T, Hijazi Z, Lindbäck J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2021 Aug 06; doi: 10.1093/cvr/cvab262. Epub 2021 Aug 06. PMID: 34358298.
Copy Download .nbib Format: NLM
Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study.

The Lancet. Digital health

Tromp J, Seekings PJ, Hung CL, Iversen MB, Frost MJ, Ouwerkerk W, Jiang Z, Eisenhaber F, Goh RSM, Zhao H, Huang W, Ling LH, Sim D, Cozzone P, Richards AM, Lee HK, Solomon SD, Lam CSP, Ezekowitz JA.
PMID: 34863649
Lancet Digit Health. 2021 Dec 01; doi: 10.1016/S2589-7500(21)00235-1. Epub 2021 Dec 01.

BACKGROUND: Echocardiography is the diagnostic modality for assessing cardiac systolic and diastolic function to diagnose and manage heart failure. However, manual interpretation of echocardiograms can be time consuming and subject to human error. Therefore, we developed a fully automated...

Cite
Tromp J, Seekings PJ, Hung CL, et al. Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. Lancet Digit Health. 2021;doi: 10.1016/S2589-7500(21)00235-1.
Tromp, J., Seekings, P. J., Hung, C. L., Iversen, M. B., Frost, M. J., Ouwerkerk, W., Jiang, Z., Eisenhaber, F., Goh, R. S. M., Zhao, H., Huang, W., Ling, L. H., Sim, D., Cozzone, P., Richards, A. M., Lee, H. K., Solomon, S. D., Lam, C. S. P., & Ezekowitz, J. A. (2021). Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. The Lancet. Digital health, . https://doi.org/10.1016/S2589-7500(21)00235-1
Tromp, Jasper, et al. "Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study." The Lancet. Digital health vol. (2021). doi: https://doi.org/10.1016/S2589-7500(21)00235-1
Tromp J, Seekings PJ, Hung CL, Iversen MB, Frost MJ, Ouwerkerk W, Jiang Z, Eisenhaber F, Goh RSM, Zhao H, Huang W, Ling LH, Sim D, Cozzone P, Richards AM, Lee HK, Solomon SD, Lam CSP, Ezekowitz JA. Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. Lancet Digit Health. 2021 Dec 01; doi: 10.1016/S2589-7500(21)00235-1. Epub 2021 Dec 01. PMID: 34863649.
Copy Download .nbib Format: NLM
The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial.

ESC heart failure

Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Piña IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, O'Connor CM, Felker GM.
PMID: 34784657
ESC Heart Fail. 2021 Nov 16; doi: 10.1002/ehf2.13692. Epub 2021 Nov 16.

AIMS: N-terminal pro-b-type natriuretic peptide (NT-proBNP) values may be influenced by patient factors beyond the severity of illness, including atrial fibrillation (AF), renal dysfunction, or increased body mass index (BMI). We hypothesized that these factors may influence the achievement...

Cite
Ezekowitz JA, Alemayehu W, Rathwell S, et al. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Fail. 2021;doi: 10.1002/ehf2.13692.
Ezekowitz, J. A., Alemayehu, W., Rathwell, S., Grant, A. D., Fiuzat, M., Whellan, D. J., Ahmad, T., Adams, K., Piña, I. L., Cooper, L. S., Januzzi, J. L., Leifer, E. S., Mark, D., O'Connor, C. M., & Felker, G. M. (2021). The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC heart failure, . https://doi.org/10.1002/ehf2.13692
Ezekowitz, Justin A, et al. "The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial." ESC heart failure vol. (2021). doi: https://doi.org/10.1002/ehf2.13692
Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Piña IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, O'Connor CM, Felker GM. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Fail. 2021 Nov 16; doi: 10.1002/ehf2.13692. Epub 2021 Nov 16. PMID: 34784657.
Copy Download .nbib Format: NLM
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model.

Journal of cardiac failure

Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O'Connor CM.
PMID: 34216757
J Card Fail. 2021 May 26; doi: 10.1016/j.cardfail.2021.05.016. Epub 2021 May 26.

BACKGROUND: Prediction of outcomes in patients with heart failure (HF) may inform prognosis, clinical decisions regarding treatment selection, and new trial planning. The VICTORIA trial included high-risk patients with HF and reduced ejection fraction and a recent worsening HF...

Cite
Mentz RJ, Mulder H, Mosterd A, et al. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. J Card Fail. 2021;doi: 10.1016/j.cardfail.2021.05.016.
Mentz, R. J., Mulder, H., Mosterd, A., Sweitzer, N. K., Senni, M., Butler, J., Ezekowitz, J. A., Lam, C. S. P., Pieske, B., Ponikowski, P., Voors, A. A., Anstrom, K. J., Armstrong, P. W., O'Connor, C. M. (2021). Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. Journal of cardiac failure, . https://doi.org/10.1016/j.cardfail.2021.05.016
Mentz, Robert J, et al. "Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model." Journal of cardiac failure vol. (2021). doi: https://doi.org/10.1016/j.cardfail.2021.05.016
Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O'Connor CM. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. J Card Fail. 2021 May 26; doi: 10.1016/j.cardfail.2021.05.016. Epub 2021 May 26. PMID: 34216757.
Copy Download .nbib Format: NLM
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.

Journal of cardiac failure

Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O'connor CM, Hernandez AF.
PMID: 34217593
J Card Fail. 2021 Jun 24; doi: 10.1016/j.cardfail.2021.05.016. Epub 2021 Jun 24.

BACKGROUND: The prediction of outcomes in patients with heart failure (HF) may inform prognosis, clinical decisions regarding treatment selection, and new trial planning. The VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction included high-risk patients...

Cite
Mentz RJ, Mulder H, Mosterd A, et al. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. J Card Fail. 2021;doi: 10.1016/j.cardfail.2021.05.016.
Mentz, R. J., Mulder, H., Mosterd, A., Sweitzer, N. K., Senni, M., Butler, J., Ezekowitz, J. A., Lam, C. S. P., Pieske, B., Ponikowski, P., Voors, A. A., Anstrom, K. J., Armstrong, P. W., O'connor, C. M., Hernandez, A. F. (2021). Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of cardiac failure, . https://doi.org/10.1016/j.cardfail.2021.05.016
Mentz, Robert J, et al. "Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial." Journal of cardiac failure vol. (2021). doi: https://doi.org/10.1016/j.cardfail.2021.05.016
Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O'connor CM, Hernandez AF. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. J Card Fail. 2021 Jun 24; doi: 10.1016/j.cardfail.2021.05.016. Epub 2021 Jun 24. PMID: 34217593.
Copy Download .nbib Format: NLM
Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design.

Journal of thrombosis and thrombolysis

Fiore L, Brophy M, Peduzzi P, Lu D, Sacco J, Colling C, Ezekowitz M.
PMID: 10751795
J Thromb Thrombolysis. 1998 Sep;6(2):133-140. doi: 10.1023/A:1008853622289.

It is now agreed that the majority of acute myocardial infarctions result from intracoronary thrombosis at sites of atherosclerotic plaque that have been disrupted. In 1947 Nicol and Fassett published the first clinical paper suggesting that agents interfering with...

Cite
Fiore L, Brophy M, Peduzzi P, et al. Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design. J Thromb Thrombolysis. 1998;6(2):133-140doi: 10.1023/A:1008853622289.
Fiore, L., Brophy, M., Peduzzi, P., Lu, D., Sacco, J., Colling, C., & Ezekowitz, M. (1998). Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design. Journal of thrombosis and thrombolysis, 6(2), 133-140. https://doi.org/10.1023/A:1008853622289
Fiore, et al. "Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design." Journal of thrombosis and thrombolysis vol. 6,2 (1998): 133-140. doi: https://doi.org/10.1023/A:1008853622289
Fiore L, Brophy M, Peduzzi P, Lu D, Sacco J, Colling C, Ezekowitz M. Combination Hemotherapy and Mortality Prevention (CHAMP) Study Rationale and Design. J Thromb Thrombolysis. 1998 Sep;6(2):133-140. doi: 10.1023/A:1008853622289. PMID: 10751795.
Copy Download .nbib Format: NLM
Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials.

Contemporary clinical trials

Harrington J, Gouda P, Ezekowitz J, Mentz RJ.
PMID: 34863929
Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01.

Clinical trials are a cornerstone of modern medicine and form the backbone of evidence that is used to create evidence-based guidelines. Contemporary clinical trials have tended to be quite explanatory, assessing an intervention in ideal conditions with highlyprotocolized interventions,...

Cite
Harrington J, Gouda P, Ezekowitz J, et al. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021;113:106646doi: 10.1016/j.cct.2021.106646.
Harrington, J., Gouda, P., Ezekowitz, J., & Mentz, R. J. (2021). Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemporary clinical trials, 113106646. https://doi.org/10.1016/j.cct.2021.106646
Harrington, Josephine, et al. "Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials." Contemporary clinical trials vol. 113 (2021): 106646. doi: https://doi.org/10.1016/j.cct.2021.106646
Harrington J, Gouda P, Ezekowitz J, Mentz RJ. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01. PMID: 34863929.
Copy Download .nbib Format: NLM
A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency.

Case reports in medicine

Leung AA, Chan AK, Ezekowitz JA, Leung AK.
PMID: 19893767
Case Rep Med. 2009;2009:183125. doi: 10.1155/2009/183125. Epub 2009 Nov 04.

3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) lyase deficiency is an inborn error of metabolism characterized by impairment of ketogenesis and leucine catabolism resulting in an organic acidopathy. In 1994, a case of dilated cardiomyopathy and fatal arrhythmia was reported in a...

Cite
Leung AA, Chan AK, Ezekowitz JA, et al. A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. Case Rep Med. 2009;2009:183125doi: 10.1155/2009/183125.
Leung, A. A., Chan, A. K., Ezekowitz, J. A., & Leung, A. K. (2009). A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. Case reports in medicine, 2009183125. https://doi.org/10.1155/2009/183125
Leung, Alexander A C, et al. "A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency." Case reports in medicine vol. 2009 (2009): 183125. doi: https://doi.org/10.1155/2009/183125
Leung AA, Chan AK, Ezekowitz JA, Leung AK. A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. Case Rep Med. 2009;2009:183125. doi: 10.1155/2009/183125. Epub 2009 Nov 04. PMID: 19893767; PMCID: PMC2773375.
Copy Download .nbib Format: NLM
Diabetes and heart failure in the crosshairs: where is the target?.

European journal of heart failure

Ezekowitz JA, Armstrong PW.
PMID: 28052547
Eur J Heart Fail. 2017 Jan;19(1):66-68. doi: 10.1002/ejhf.703.

No abstract available.

Cite
Ezekowitz JA, Armstrong PW. Diabetes and heart failure in the crosshairs: where is the target?. Eur J Heart Fail. 2017;19(1):66-68doi: 10.1002/ejhf.703.
Ezekowitz, J. A., & Armstrong, P. W. (2017). Diabetes and heart failure in the crosshairs: where is the target?. European journal of heart failure, 19(1), 66-68. https://doi.org/10.1002/ejhf.703
Ezekowitz, Justin A, and Armstrong, Paul W. "Diabetes and heart failure in the crosshairs: where is the target?." European journal of heart failure vol. 19,1 (2017): 66-68. doi: https://doi.org/10.1002/ejhf.703
Ezekowitz JA, Armstrong PW. Diabetes and heart failure in the crosshairs: where is the target?. Eur J Heart Fail. 2017 Jan;19(1):66-68. doi: 10.1002/ejhf.703. PMID: 28052547.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 86 entries